A
Agilent Technologies, Inc. [A] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
A Stock Summary
Top A Correlated Resources
A
Top 10 Correlated ETFs
A
Top 10 Correlated Stocks
A
In the News
Agilent Technologies, Inc. (A) Evercore ISI HealthCONx Conference 2023 Transcript
Agilent Technologies, Inc. (NYSE:A ) Evercore ISI HealthCONx Conference 2023 November 29, 2023 10:50 AM ET Company Participants Mike McMullen - President and Chief Executive Officer Bob McMahon - Chief Financial Officer Conference Call Participants Vijay Kumar - Evercore ISI Vijay Kumar Thanks everyone for joining us this morning. I'm Vijay Kumar.
Why I Made Big Changes To My Dividend Growth Portfolio
I've made significant changes to my portfolio due to buying a new house and selling stocks from my portfolio to raise cash. My goal is to prioritize building a passive income stream, but I recognize the value of investing in a new home for improved quality of life. In this article, I discuss different options to pay for the new home, including taking out a mortgage or selling more stock if mortgage rates remain high.
Earn A Potential 10% Plus Income With Options (December 2023)
We explain why selling cash-covered puts and covered calls are relatively safe choices for earning a high income. We will discuss how to formulate a sustainable and repeatable options income strategy. In this monthly series, we present how to go about selecting the right kind of stocks for options income. We present two lists of 10 stocks with multiple scenarios: PUT options, CALL options, and deep-in-the-money CALL options.
Down 24% This Year Will Agilent Technologies Stock Rebound To Its Pre-Inflation High Of $175?
The company's top line has contracted in the recent past due to lower sales in China.
Agilent (A) Q4 Earnings & Revenues Beat Estimates, Down Y/Y
Agilent's (A) fourth-quarter fiscal 2023 results are hurt by weakness in the LSAG segment and softness in the China market.
Agilent (A) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Agilent (A) give a sense of how its business performed in the quarter ended October 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Agilent Technologies, Inc. (A) Q4 2023 Earnings Call Transcript
Agilent Technologies, Inc. (NYSE:A ) Q4 2023 Earnings Conference Call November 20, 2023 4:30 PM ET Company Participants Parmeet Ahuja - IR Mike McMullen - President and CEO Robert McMahon - SVP and CFO Sam Raha - President, Agilent Diagnostics & Genomics Group Padraig McDonnell - President, Agilent CrossLab Group Phil Binns - President of the Agilent Life Sciences and Applied Markets Group Conference Call Participants Vijay Kumar - Evercore ISI Patrick Donnelly - Citigroup Inc. Matt Sykes - Goldman Sachs Rachel Vatnsdal - JPMorgan Derik De Bruin - Bank of America Jack Meehan - Nephron Research Puneet Souda - Leerink Partners Josh Waldman - Cleveland Research Daniel Brennan - TD Cowen Dan Leonard - UBS Operator Ladies and gentlemen, welcome to the Agilent Technologies Q4 2023 Earnings Conference Call. My name is Bo and I will be coordinating your call today.
Agilent Technologies stock higher as 4Q results beat estimates
Agilent Technologies (NYSE:A) Inc after Monday's close announced fourth quarter 2023 financial results that exceeded expectations on both the top and bottom lines. The analytical and clinical laboratory technologies provider's adjusted earnings per share (EPS) for the period declined 10% year over year to $1.38, while its revenue fell 9% to $1.69 billion.
3 Biotech Stocks With Big-Time Breakthrough Potential
In a world in constant evolution and growth, more and more companies are needed that are committed to development and research in the health area. These biotech companies are not only doing the job, but also have potential for future growth.
Earnings Exchange: Medtronic, Agilent Technologies & Trip.com
Ari Wald, managing director and head of technical analysis at Oppenheimer, joins 'The Exchange' to discuss Medtronic, Agilent Technologies, and Trip.com.
A Financial details
A Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-10-31
| Metric | History | 2019-10-31 | 2020-10-31 | 2021-10-31 | 2022-10-31 | 2023-10-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 16.44 | 17.28 | 20.79 | 22.9 | 23.24 | |
| Net income per share | 3.41 | 2.33 | 3.98 | 4.19 | 4.22 | |
| Operating cash flow per share | 3.25 | 2.98 | 4.88 | 4.39 | 6.03 | |
| Free cash flow per share | 2.75 | 2.6 | 4.26 | 3.41 | 5.01 | |
| Cash per share | 4.4 | 4.66 | 5.18 | 3.52 | 5.41 | |
| Book value per share | 15.12 | 15.77 | 17.73 | 17.69 | 19.88 | |
| Tangible book value per share | -3.37 | -1.27 | -1.8 | -1.02 | 4.8 | |
| Share holders equity per share | 15.12 | 15.77 | 17.73 | 17.69 | 19.88 | |
| Interest debt per share | 7.9 | 7.89 | 9.24 | 9.54 | 9.63 | |
| Market cap | 23.79B | 31.55B | 47.75B | 41.37B | 30.39B | |
| Enterprise value | 24.81B | 32.46B | 48.99B | 43.08B | 31.54B | |
| P/E ratio | 22.21 | 43.87 | 39.46 | 32.99 | 24.51 | |
| Price to sales ratio | 4.61 | 5.91 | 7.56 | 6.04 | 4.45 | |
| POCF ratio | 23.3 | 34.25 | 32.15 | 31.53 | 17.15 | |
| PFCF ratio | 27.5 | 39.33 | 36.84 | 40.52 | 20.62 | |
| P/B Ratio | 5.01 | 6.47 | 8.86 | 7.82 | 5.2 | |
| PTB ratio | 5.01 | 6.47 | 8.86 | 7.82 | 5.2 | |
| EV to sales | 4.81 | 6.08 | 7.75 | 6.29 | 4.62 | |
| Enterprise value over EBITDA | 20.15 | 26.44 | 27.8 | 22.62 | 18.5 | |
| EV to operating cash flow | 24.3 | 35.25 | 32.99 | 32.84 | 17.8 | |
| EV to free cash flow | 28.68 | 40.48 | 37.8 | 42.2 | 21.39 | |
| Earnings yield | 0.05 | 0.02 | 0.03 | 0.03 | 0.04 | |
| Free cash flow yield | 0.04 | 0.03 | 0.03 | 0.02 | 0.05 | |
| Debt to equity | 0.51 | 0.48 | 0.51 | 0.52 | 0.47 | |
| Debt to assets | 0.25 | 0.25 | 0.25 | 0.26 | 0.25 | |
| Net debt to EBITDA | 0.83 | 0.75 | 0.71 | 0.9 | 0.67 | |
| Current ratio | 1.53 | 2.33 | 2.22 | 2.03 | 2.61 | |
| Interest coverage | 12.72 | 10.85 | 16.63 | 19.26 | 14.21 | |
| Income quality | 0.95 | 1.28 | 1.23 | 1.05 | 1.43 | |
| Dividend Yield | 0.01 | 0.01 | 0 | 0.01 | 0.01 | |
| Payout ratio | 0.19 | 0.31 | 0.2 | 0.2 | 0.21 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0.08 | 0.09 | 0.07 | 0.07 | 0.07 | |
| Intangibles to total assets | 0.5 | 0.46 | 0.46 | 0.45 | 0.41 | |
| Capex to operating cash flow | -0.15 | -0.13 | -0.13 | -0.22 | -0.17 | |
| Capex to revenue | -0.03 | -0.02 | -0.03 | -0.04 | -0.04 | |
| Capex to depreciation | -0.66 | -0.39 | -0.59 | -0.92 | -1.1 | |
| Stock based compensation to revenue | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Graham number | 34.07 | 28.73 | 39.84 | 40.86 | 43.44 | |
| ROIC | 0.15 | 0.1 | 0.15 | 0.17 | 0.15 | |
| Return on tangible assets | 0.23 | 0.14 | 0.21 | 0.22 | 0.2 | |
| Graham Net | -7.28 | -7.04 | -8.05 | -8.7 | -6.27 | |
| Working capital | 1.11B | 1.95B | 2.09B | 1.92B | 2.58B | |
| Tangible asset value | 48M | 440M | 433M | 516M | 1.41B | |
| Net current asset value | -1.52B | -1.34B | -1.52B | -1.45B | -732M | |
| Invested capital | 0.51 | 0.48 | 0.51 | 0.52 | 0.47 | |
| Average receivables | 853M | 984M | 1.11B | 1.29B | 1.35B | |
| Average payables | 347M | 354M | 400M | 513M | 499M | |
| Average inventory | 658.5M | 699.5M | 775M | 934M | 1.03B | |
| Days sales outstanding | 65.75 | 70.96 | 67.7 | 74.89 | 68.96 | |
| Days payables outstanding | 54.8 | 51.64 | 55.9 | 67.72 | 45.3 | |
| Days of inventory on hand | 105.1 | 105.04 | 104.04 | 121.2 | 111.73 | |
| Receivables turnover | 5.55 | 5.14 | 5.39 | 4.87 | 5.29 | |
| Payables turnover | 6.66 | 7.07 | 6.53 | 5.39 | 8.06 | |
| Inventory turnover | 3.47 | 3.48 | 3.51 | 3.01 | 3.27 | |
| ROE | 0.23 | 0.15 | 0.22 | 0.24 | 0.21 | |
| Capex per share | -0.5 | -0.39 | -0.62 | -0.97 | -1.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-10-31 for Q4
| Metric | History | 2022-10-31 | 2023-01-31 | 2023-04-30 | 2023-07-31 | 2023-10-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 6.25 | 5.93 | 5.8 | 5.69 | 5.78 | |
| Net income per share | 1.24 | 1.19 | 1.02 | 0.38 | 1.63 | |
| Operating cash flow per share | 1.51 | 1 | 1.34 | 1.91 | 1.77 | |
| Free cash flow per share | 1.28 | 0.74 | 1.15 | 1.64 | 1.48 | |
| Cash per share | 3.56 | 4.25 | 3.97 | 4.52 | 5.45 | |
| Book value per share | 17.87 | 18.95 | 19.53 | 18.9 | 20.02 | |
| Tangible book value per share | -1.03 | 0.02 | 3.39 | 3.65 | 4.83 | |
| Share holders equity per share | 17.87 | 18.95 | 19.53 | 18.9 | 20.02 | |
| Interest debt per share | 9.43 | 10.12 | 9.31 | 9.57 | 9.44 | |
| Market cap | 40.95B | 45.02B | 40.28B | 35.8B | 30.18B | |
| Enterprise value | 42.67B | 46.74B | 41.84B | 37.26B | 31.33B | |
| P/E ratio | 27.82 | 31.97 | 33.34 | 80.63 | 15.89 | |
| Price to sales ratio | 22.15 | 25.64 | 23.46 | 21.41 | 17.88 | |
| POCF ratio | 91.41 | 152.08 | 101.21 | 63.7 | 58.5 | |
| PFCF ratio | 108.34 | 204.62 | 118.12 | 74.43 | 69.87 | |
| P/B Ratio | 7.74 | 8.03 | 6.97 | 6.44 | 5.16 | |
| PTB ratio | 7.74 | 8.03 | 6.97 | 6.44 | 5.16 | |
| EV to sales | 23.08 | 26.62 | 24.37 | 22.28 | 18.56 | |
| Enterprise value over EBITDA | 77.44 | 93.1 | 88.64 | 164.14 | 62.16 | |
| EV to operating cash flow | 95.24 | 157.89 | 105.12 | 66.3 | 60.72 | |
| EV to free cash flow | 112.88 | 212.44 | 122.69 | 77.46 | 72.52 | |
| Earnings yield | 0.01 | 0.01 | 0.01 | 0 | 0.02 | |
| Free cash flow yield | 0.01 | 0 | 0.01 | 0.01 | 0.01 | |
| Debt to equity | 0.52 | 0.53 | 0.47 | 0.5 | 0.47 | |
| Debt to assets | 0.26 | 0.27 | 0.25 | 0.26 | 0.25 | |
| Net debt to EBITDA | 3.11 | 3.43 | 3.3 | 6.43 | 2.27 | |
| Current ratio | 2.03 | 2.11 | 2.37 | 2.29 | 2.61 | |
| Interest coverage | 20.48 | 17.04 | 15.96 | 5.54 | 18.55 | |
| Income quality | 1.22 | 0.84 | 1.32 | 5.06 | 1.09 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0.17 | 0.19 | 0.22 | 0.59 | 0.14 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0.06 | 0.07 | 0.07 | 0.07 | 0.07 | |
| Intangibles to total assets | 0.45 | 0.44 | 0.44 | 0.42 | 0.41 | |
| Capex to operating cash flow | -0.16 | -0.26 | -0.14 | -0.14 | -0.16 | |
| Capex to revenue | -0.04 | -0.04 | -0.03 | -0.05 | -0.05 | |
| Capex to depreciation | -0.96 | -1.13 | -0.8 | -1.14 | -1.35 | |
| Stock based compensation to revenue | 0.01 | 0.03 | 0.01 | 0.02 | 0.01 | |
| Graham number | 22.36 | 22.52 | 21.17 | 12.67 | 27.07 | |
| ROIC | 0.05 | 0.04 | 0.04 | 0.01 | 0.05 | |
| Return on tangible assets | 0.06 | 0.06 | 0.05 | 0.02 | 0.08 | |
| Graham Net | -8.79 | -8.12 | -7.55 | -7.65 | -6.32 | |
| Working capital | 1.92B | 2.14B | 2.28B | 2.27B | 2.58B | |
| Tangible asset value | 516M | 816M | 1B | 1.07B | 1.41B | |
| Net current asset value | -1.45B | -1.23B | -1.06B | -1.09B | -732M | |
| Invested capital | 0.52 | 0.53 | 0.47 | 0.5 | 0.47 | |
| Average receivables | 1.38B | 1.43B | 1.43B | 1.37B | 1.32B | |
| Average payables | 569M | 560M | 509.5M | 465.5M | 435M | |
| Average inventory | 1.02B | 1.07B | 1.11B | 1.09B | 1.05B | |
| Days sales outstanding | 68.39 | 74.78 | 73.44 | 72.08 | 68.83 | |
| Days payables outstanding | 62.37 | 61.68 | 54.36 | 40.12 | 48.67 | |
| Days of inventory on hand | 111.61 | 126.89 | 125.18 | 95.15 | 120.04 | |
| Receivables turnover | 1.32 | 1.2 | 1.23 | 1.25 | 1.31 | |
| Payables turnover | 1.44 | 1.46 | 1.66 | 2.24 | 1.85 | |
| Inventory turnover | 0.81 | 0.71 | 0.72 | 0.95 | 0.75 | |
| ROE | 0.07 | 0.06 | 0.05 | 0.02 | 0.08 | |
| Capex per share | -0.24 | -0.26 | -0.19 | -0.28 | -0.29 |
A Frequently Asked Questions
What is Agilent Technologies, Inc. stock symbol ?
Agilent Technologies, Inc. is a US stock , located in Santa clara of Ca and trading under the symbol A
Is Agilent Technologies, Inc. buy or a sell ?
8 stock analysts have 8 predictions with a medium analyst target price of $148.88. The lowest prediction is $105 and the highest is $170
What is A stock prediction ?
With a median analyst target price of $112.5, 2 stock analysts have made 2 forecasts in last 90 days. $105 is the lowest and $120 is the greatest projection.
What is Agilent Technologies, Inc. stock quote today ?
Agilent Technologies, Inc. stock price is $127.2 today.
Is Agilent Technologies, Inc. stock public?
Yes, Agilent Technologies, Inc. is a publicly traded company.
Company Profile
- Volume Average 2.14M
- Market Capitalization 37.22B
- Employee 18K
- CEO Mr. Michael R. McMullen
- Headquarters Santa Clara,CA,US
- IPO Date 1999-11-18
-
Website
https://www.agilent.com 
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide. It also offers immunohistochemistry in situ hybridization, and hematoxylin and eosin staining and special staining; consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops liquid-based pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.
